Titan Pharmaceuticals

Titan Pharmaceuticals has announced that the first patient has been treated in a Phase I/II trial of its ropinirole subdermal implant for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Read more


With patient adherence and prevention of overdose hot topics for pharma, regulatory and healthcare sectors, the rise of implants for the sustained and controlled delivery of drugs is perhaps an inevitable trend. Read more


The Psychopharmacologic Drugs Advisory Committee (PDAC) of the US Food and Drug Administration (FDA) has voted in favour of approving Probuphine, an implant to treat opioid addiction Read more